Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

PCV20 includes all 13 serotypes in PCV13, along with seven additional serotypes “that are responsible for a substantial amount of the residual disease burden,” he added.

Alongside its results, the company announced a significant product launch. On August 11, Pfizer rolled out its ...

A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Pfizer has introduced its 20-valent pneumococcal conjugate vaccine, PCV20, in India to provide protection against 20 serotypes of pneumococcal disease. The single-shot vaccine is aimed at adults, ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

The study compared VAX-31 to PCV20 in 1,015 healthy adults aged 50 and older. The company has selected VAX-31 to advance to an adult Phase 3 program.

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Merck (MRK) said Thursday that in two Phase 3 trials its 21-valent pneumococcal shot outperformed PCV20 marketed as Prevnar 20 by Pfizer (PFE). Read more here.

In a statement, Pfizer stated PCV20 offers a broader pneumococcal conjugate vaccine option in Malaysia, providing coverage against 20 serotypes of Streptococcus pneumoniae, the bacteria responsible ...